Phospholipase is one of a very complex group of enzymes that converts phospholipids into fatty acids and other compounds. The enzymatic reaction that phospholipases catalyze serves to define them. Phospholipase A, which has members A1 and A2, Phospholipase B, which can perform both A1 and A2 reactions, Phospholipase C, and Phospholipase D are the classes.
Fatty acids and lysophospholipids are produced when phospholipase A2 (PLA2) catalyzes the hydrolysis of the sn-2 position of glycerophospholipids. Phospholipase C (PLC) transforms inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) from phosphatidylinositol 4,5-bisphosphate (PIP2). DAG and IP3 each regulate a variety of cellular processes and serve as a starting point for the creation of additional significant signaling molecules. PLC serves as the hub of numerous significant interconnected regulatory networks. The production of the lipid second messenger phosphatidic acid (PA), which is involved in fundamental cellular processes like membrane trafficking, actin cytoskeleton remodeling, cell proliferation, and cell survival, is carried out by the crucial enzyme phospholipase D (PLD).
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V0844 | Darapladib (SB-480848) | 356057-34-6 | Darapladib (formerly also known as SB-480848; SB 480848; SB480848),a substituted pyrimidone, is a novel, potent and reversible inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitorwith potential anti-inflammatory activity. |
|
V3034 | FIPI | 939055-18-2 | FIPI is a derivative of halopemide which potently and selectively inhibits both PLD1 (phospholipase D) and PLD2 with IC50 values of 25 nM and 20 nM, respectively. |
|
V34665 | KY-226 | 1621673-53-7 | KY-226 is a novel, selective, orally bioactive and allosteric inhibitor of protein tyrosine phosphatase 1B (PTP1B) with anIC50of 0.25 μM, and without PPARγ agonist activity. |
|
V2945 | ML348 | 899713-86-1 | ML348 (also known as CID 3238952; SID 160654487) is a reversible inhibitor of LYPLA1 (Lysophospholipase 1) with an IC50 value of 210 nM. |
|
V0845 | U73122 | 112648-68-7 | U73122 (U 73122; U-73122) is a novel and potent phospholipase C (PLC) and 5-LO (5-lipoxygenase) inhibitor with potential anti-inflammatory activity. |
|
V24392 | VU-0155069 | 1130067-06-9 | VU0155069 (CAY10593), compound 69 is a selective phospholipase D1 (PLD1) inhibitor (antagonist) with IC50 of 46 nM. |
|
V0843 | Tanshinone I (Tanshinone A) | 568-73-0 | Tanshinone I (Tanshinone A; dihydrotanshinone, tanshinone IIA), a natural pigment isolated from the herbal medicine Salvia miltiorrhiza Bunge, is a potent inhibitor of type IIA human recombinant sPLA2 with important biological activity. |
|
V0839 | Varespladib (LY 315920) | 172732-68-2 | Varespladib (formerly A-002; A 002; LY315920; LY-315920) is a investigational drug with thepotential for treating inflammatory diseases such as acute coronary syndrome and acute chest syndrome as well as snakebite. |
|
V0841 | Halobetasol Propionate | 66852-54-8 | Halobetasol Propionate (BMY30056, CGP14458;BMY 30056, CGP 14458;BMY-30056; CGP-14458; Ulobetasol propionate)is a potent and synthetic corticosteroid with anti-inflammatory activity. |
|
V0840 | Clofazimine | 2030-63-9 | Clofazimine (B-663;G-30320; NSC-141046; Lamprene; Lampren; Chlofazimine; Clofazimina),an antibacterial drug, is a rhimophenazine-based dye that is fat-soluble, and was originally developed as an anti-TB/tuberculosis drug but now used for treating leprosy. |
|
V1970 | Quinacrine 2HCl (Mepacrine; SN-390) | 69-05-6 | Quinacrine 2HCl (Mepacrine; SN-390) is a lipophilic cationic drug with multiple actions that is commonly used as an anti-protozoal agent. |
|
V0842 | Polydatin | 65914-17-2 | Polydatin (Reservatrol 3-β-mono-D-Glucoside; Piceid)is a naturally occuring stilbene and aprecursor of resveratrolas well as a crystal component extracted from the root stem of perennial herbage Polygonum Cuspidatum Sieb. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
